| Nseir, Georges |
| Recruiting | N/A | 100 | US | AngioSafe Peripheral CTO Crossing System | AngioSafe, Inc., Veranex, Inc. | Peripheral Artery Occlusion, Peripheral Arterial Disease | 02/23 | 02/23 | | |
ECLIPSE, NCT03108456: Evaluation of Treatment Strategies for Severe CaLcIfic Coronary Arteries: Orbital Atherectomy vs. Conventional Angioplasty Technique Prior to Implantation of Drug-Eluting StEnts: The Trial |
|
|
| Active, not recruiting | N/A | 2005 | US | Orbital Atherectomy, Balloon | Abbott Medical Devices, Cardiovascular Research Foundation, New York | Coronary Artery Disease, Ischemic Heart Disease, Non ST Segment Elevation Myocardial Infarction | 06/24 | 06/25 | | |
| Tendler, ry |
NCT04496518: Personalized Therapy Study - Intrinsic Antitachycardia Pacing Post-Approval Study (iATP PAS) |
|
|
| Recruiting | N/A | 2200 | Europe, US | Intrinsic Antitachycardia Pacing (iATP) Therapy | Medtronic | Ventricular Tachycardia | 01/25 | 01/27 | | |
NCT04489225: Personalized Therapy Study - HFRS (TriageHF) Post Approval Study |
|
|
| Recruiting | N/A | 2200 | Europe, US | Observational | Medtronic | Heart Failure | 01/25 | 01/27 | | |
ASQ, NCT04024943: Personalized Therapy Study - Attain Stability Quad Post-Approval Study |
|
|
| Active, not recruiting | N/A | 1008 | Europe, US | Quadripolar LV Lead, Medtronic CRT-P, Medtronic CRT-D | Medtronic | Heart Failure | 01/27 | 04/27 | | |
| Dib, Nabil |
NCT06292013: A Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(a) - ACCLAIM-Lp(a) |
|
|
| Recruiting | 3 | 12500 | Europe, Canada, Japan, US, RoW | Lepodisiran Sodium, LY3819469, Placebo | Eli Lilly and Company | Atherosclerotic Cardiovascular Disease (ASCVD), Elevated Lp(a) | 03/29 | 03/29 | | |
VICTORION-2P, NCT05030428: Study of Inclisiran to Prevent Cardiovascular (CV) Events in Participants With Established Cardiovascular Disease |
|
|
| Active, not recruiting | 3 | 17006 | Europe, Canada, Japan, US, RoW | Inclisiran sodium 300 mg, Placebo | Novartis Pharmaceuticals | Atherosclerotic Cardiovascular Disease | 10/27 | 10/27 | | |
| Active, not recruiting | N/A | 1720 | Europe, Canada, US | Microport Firehawk stent, MicroPort Firehawk rapamycin target eluting stent, 2nd generation DES (XIENCE family, Promus family, Resolute/Onyx family/Endeavor, and Orsiro stent) | Shanghai MicroPort Medical (Group) Co., Ltd. | Coronary Artery Disease | 06/24 | 06/27 | | |
| Recruiting | N/A | 560 | Europe, US | Impella CP®, Standard of Care | Abiomed Inc. | ST-segment Elevation Myocardial Infarction (STEMI), Cardiogenic Shock | 04/26 | 12/27 | | |
NCT03142152: The EMPOWER Trial - The Carillon Mitral Contour System® in Treating Heart Failure With at Least Mild FMR |
|
|
| Recruiting | N/A | 300 | Europe, US | Carillon Mitral Contour System, Carillon, Percutaneous mitral valve repair, Guideline Directed Heart Failure Medication | Cardiac Dimensions, Inc. | Functional Mitral Regurgitation, Heart Failure, Mitral Valve Insufficiency, Heart Diseases, Cardiovascular Diseases, Heart Valve Diseases | 12/26 | 12/30 | | |
NCT05169840: Genetic Risk Stratification for Primary Prevention of CAD in Men and Pre & Post-menopausal Women |
|
|
| Recruiting | N/A | 2000 | US | Genetic Risk Score for Coronary Artery Disease, Conventional Risk Score for Coronary Artery Disease | St. Joseph's Hospital and Medical Center, Phoenix, Chandler Regional Medical Center, Mercy Gilbert Medical Center | Coronary Artery Disease, Genetic Predisposition to Disease | 06/24 | 06/24 | | |
| Lillo, Joseph |
| Completed | 3 | 295 | Europe, US, RoW | Telmisartan 10 mg/amlodipine 1.25 mg/indapamide 0.625 mg, Telmisartan 20 mg/amlodipine 2.5 mg/indapamide 1.25 mg, Placebo | George Medicines PTY Limited | Hypertension | 09/23 | 10/23 | | |
GMRx2_ACT, NCT04518293: Efficacy and Safety of GMRx2 Compared to Dual Combinations for the Treatment of Hypertension |
|
|
| Completed | 3 | 1385 | Europe, US, RoW | Telmisartan 20 mg/amlodipine 2.5 mg/indapamide 1.25 mg, telmisartan 40 mg/amlodipine 5 mg/indapamide 2.5 mg, Telmisartan 20 mg/amlodipine 2.5 mg ., telmisartan 40 mg/amlodipine 5 mg, Telmisartan 20 mg/indapamide 1.25 mg, telmisartan 40 mg/indapamide 2.5 mg, Amlodipine 2.5 mg/indapamide 1.25 mg, amlodipine 5 mg/indapamide 2.5 mg | George Medicines PTY Limited | Hypertension | 08/23 | 09/23 | | |
NCT06292013: A Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(a) - ACCLAIM-Lp(a) |
|
|
| Recruiting | 3 | 12500 | Europe, Canada, Japan, US, RoW | Lepodisiran Sodium, LY3819469, Placebo | Eli Lilly and Company | Atherosclerotic Cardiovascular Disease (ASCVD), Elevated Lp(a) | 03/29 | 03/29 | | |
NCT06383390: The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Renal Function in Adults Living With Obesity (TRIUMPH-OUTCOMES) |
|
|
| Recruiting | 3 | 10000 | Europe, Canada, US, RoW | Retatrutide, LY3437943, Placebo | Eli Lilly and Company | Overweight and Obesity | 02/29 | 02/29 | | |
| Active, not recruiting | 3 | 806 | Europe, Canada, Japan, US, RoW | Placebo, Mepolizumab | GlaxoSmithKline, PPD | Pulmonary Disease, Chronic Obstructive | 08/24 | 08/24 | | |
|
|
|
|
|
NCT05722522: Study of Efficacy and Safety of Secukinumab in Participants With Moderate-severe Rotator Cuff Tendinopathy |
|
|
| Active, not recruiting | 3 | 234 | Europe, Canada, US, RoW | Secukinumab, AIN457, Placebo | Novartis Pharmaceuticals | Rotator Cuff Tendinopathy | 10/24 | 12/24 | | |
ACHIEVE-4, NCT05803421: A Study of Daily Oral Orforglipron (LY3502970) Compared With Insulin Glargine in Participants With Type 2 Diabetes and Obesity or Overweight at Increased Cardiovascular Risk |
|
|
| Recruiting | 3 | 2620 | Europe, US, RoW | Orforglipron, LY3502970, Insulin Glargine | Eli Lilly and Company | Type 2 Diabetes, Obesity, Overweight or Obesity, Overweight, Cardiovascular Diseases, Chronic Kidney Disease | 04/25 | 12/25 | | |
| Active, not recruiting | 3 | 15374 | Europe, Canada, Japan, US, RoW | Tirzepatide, LY3298176, Placebo | Eli Lilly and Company | Obesity, Overweight | 10/27 | 10/27 | | |
VICTORION-2P, NCT05030428: Study of Inclisiran to Prevent Cardiovascular (CV) Events in Participants With Established Cardiovascular Disease |
|
|
| Active, not recruiting | 3 | 17006 | Europe, Canada, Japan, US, RoW | Inclisiran sodium 300 mg, Placebo | Novartis Pharmaceuticals | Atherosclerotic Cardiovascular Disease | 10/27 | 10/27 | | |
NCT04845178: Investigation of Safety and Efficacy of ABP-450 for Migraine Prevention in Adults |
|
|
| Active, not recruiting | 2 | 797 | Canada, US, RoW | ABP-450, prabotulinumtoxinA, Placebo, 0.9% sodium chloride, saline | AEON Biopharma, Inc., PPD | Migraine | 06/24 | 09/24 | | |
NCT02135705: LOWER: Lomitapide Observational Worldwide Evaluation Registry |
|
|
| Recruiting | N/A | 300 | Europe, Canada, US, RoW | Lomitapide, Juxtapid, Lojuxta | Amryt Pharma | Homozygous Familial Hypercholesterolemia | 03/28 | 09/28 | | |
|
| Mutoff, Brian |
NCT05654922: Study to Evaluate ARINA-1 in the Prevention of Bronchiolitis Obliterans Progression in Participants With Bilateral Lung Transplant |
|
|
| Recruiting | 3 | 100 | US | ARINA-1, Standard of care only | Renovion, Inc. | Pre-Bronchiolitis Obliterans Syndrome | 01/25 | 06/25 | | |
| Recruiting | 2 | 350 | Canada, US | Tocilizumab, ACTEMRA, Placebo for Tocilizumab | National Institute of Allergy and Infectious Diseases (NIAID) | Lung Transplant | 01/29 | 01/29 | | |
| Tiffany, Brian R |
NCT05894577: ACTIV-6: COVID-19 Study of Repurposed Medications - Arm F (Montelukast) |
|
|
| Completed | 3 | 1403 | US | Placebo, Montelukast | Susanna Naggie, MD, National Center for Advancing Translational Sciences (NCATS), Vanderbilt University Medical Center | Covid19 | 07/23 | 01/24 | | |
NCT04885530: ACTIV-6: COVID-19 Study of Repurposed Medications |
|
|
| Active, not recruiting | 3 | 15000 | US | Ivermectin, Ivermectin Tablets, Fluvoxamine, Fluvoxamine Maleate Tablets, Fluticasone, Fluticasone Furoate, Placebo, Montelukast, Metformin | Susanna Naggie, MD, National Center for Advancing Translational Sciences (NCATS), Vanderbilt University Medical Center | Covid19 | 06/24 | 11/24 | | |
NCT06042855: ACTIV-6: COVID-19 Study of Repurposed Medications - Arm G (Metformin) |
|
|
| Active, not recruiting | 3 | 15000 | US | Placebo, Metformin | Susanna Naggie, MD, National Center for Advancing Translational Sciences (NCATS), Vanderbilt University Medical Center | Covid19 | 06/24 | 11/24 | | |
| Completed | 2/3 | 871 | US | TXA127, TRV027, Placebo, Fostamatinib | Sean Collins, National Institutes of Health (NIH), National Heart, Lung, and Blood Institute (NHLBI) | COVID-19, SARS-CoV-2 Infection, Coronavirus Infection | 10/23 | 12/23 | | |
| Active, not recruiting | 2/3 | 125 | Canada, US | LAU-7b, fenretinide, Placebo oral capsule | Laurent Pharmaceuticals Inc. | COVID-19 Disease | 02/24 | 05/24 | | |
| Recruiting | N/A | 2000 | US | | Brian Tiffany, MD, Chandler Regional Medical Center, Arizona General Hospital, Mercy Gilbert Medical Center | COVID-19 Infection | 06/21 | 12/21 | | |
| Bond, Rachel |
| Active, not recruiting | 4 | 2476 | US | High dose potent statin, atorvastatin or rosuvastatin, ACE-I (lisinopril) or ARB (losartan), ACE-I or ARB, Aspirin, Lifestyle Counseling, PACE Lifestyle Intervention, Quality of Life Questionnaires, QOL | University of Florida, United States Department of Defense | Coronary Artery Disease | 09/24 | 12/24 | | |
CHANGE AFIB, NCT05130268: Early Dronedarone Versus Usual Care to Improve Outcomes in Persons With Newly Diagnosed Atrial Fibrillation |
|
|
| Active, not recruiting | 4 | 3000 | US | Dronedarone, Multaq | American Heart Association, Duke Clinical Research Institute, Sanofi | Atrial Fibrillation | 06/24 | 12/24 | | |
| Active, not recruiting | N/A | 227 | Canada | Resource bank, ePlatform, Health coach | McGill University Health Centre/Research Institute of the McGill University Health Centre, The Lawson Foundation | Gestational Diabetes | 06/24 | 06/24 | | |
NCT05169840: Genetic Risk Stratification for Primary Prevention of CAD in Men and Pre & Post-menopausal Women |
|
|
| Recruiting | N/A | 2000 | US | Genetic Risk Score for Coronary Artery Disease, Conventional Risk Score for Coronary Artery Disease | St. Joseph's Hospital and Medical Center, Phoenix, Chandler Regional Medical Center, Mercy Gilbert Medical Center | Coronary Artery Disease, Genetic Predisposition to Disease | 06/24 | 06/24 | | |
| Vermillion, Jennifer |
| Active, not recruiting | N/A | 1720 | Europe, Canada, US | Microport Firehawk stent, MicroPort Firehawk rapamycin target eluting stent, 2nd generation DES (XIENCE family, Promus family, Resolute/Onyx family/Endeavor, and Orsiro stent) | Shanghai MicroPort Medical (Group) Co., Ltd. | Coronary Artery Disease | 06/24 | 06/27 | | |
NCT03142152: The EMPOWER Trial - The Carillon Mitral Contour System® in Treating Heart Failure With at Least Mild FMR |
|
|
| Recruiting | N/A | 300 | Europe, US | Carillon Mitral Contour System, Carillon, Percutaneous mitral valve repair, Guideline Directed Heart Failure Medication | Cardiac Dimensions, Inc. | Functional Mitral Regurgitation, Heart Failure, Mitral Valve Insufficiency, Heart Diseases, Cardiovascular Diseases, Heart Valve Diseases | 12/26 | 12/30 | | |
NCT05169840: Genetic Risk Stratification for Primary Prevention of CAD in Men and Pre & Post-menopausal Women |
|
|
| Recruiting | N/A | 2000 | US | Genetic Risk Score for Coronary Artery Disease, Conventional Risk Score for Coronary Artery Disease | St. Joseph's Hospital and Medical Center, Phoenix, Chandler Regional Medical Center, Mercy Gilbert Medical Center | Coronary Artery Disease, Genetic Predisposition to Disease | 06/24 | 06/24 | | |
| Leon, Natalie |
ECLIPSE, NCT03108456: Evaluation of Treatment Strategies for Severe CaLcIfic Coronary Arteries: Orbital Atherectomy vs. Conventional Angioplasty Technique Prior to Implantation of Drug-Eluting StEnts: The Trial |
|
|
| Active, not recruiting | N/A | 2005 | US | Orbital Atherectomy, Balloon | Abbott Medical Devices, Cardiovascular Research Foundation, New York | Coronary Artery Disease, Ischemic Heart Disease, Non ST Segment Elevation Myocardial Infarction | 06/24 | 06/25 | | |
NCT03142152: The EMPOWER Trial - The Carillon Mitral Contour System® in Treating Heart Failure With at Least Mild FMR |
|
|
| Recruiting | N/A | 300 | Europe, US | Carillon Mitral Contour System, Carillon, Percutaneous mitral valve repair, Guideline Directed Heart Failure Medication | Cardiac Dimensions, Inc. | Functional Mitral Regurgitation, Heart Failure, Mitral Valve Insufficiency, Heart Diseases, Cardiovascular Diseases, Heart Valve Diseases | 12/26 | 12/30 | | |
NCT05169840: Genetic Risk Stratification for Primary Prevention of CAD in Men and Pre & Post-menopausal Women |
|
|
| Recruiting | N/A | 2000 | US | Genetic Risk Score for Coronary Artery Disease, Conventional Risk Score for Coronary Artery Disease | St. Joseph's Hospital and Medical Center, Phoenix, Chandler Regional Medical Center, Mercy Gilbert Medical Center | Coronary Artery Disease, Genetic Predisposition to Disease | 06/24 | 06/24 | | |
| Zumbuhl, Jennine |
| Recruiting | N/A | 2000 | US | | Brian Tiffany, MD, Chandler Regional Medical Center, Arizona General Hospital, Mercy Gilbert Medical Center | COVID-19 Infection | 06/21 | 12/21 | | |
NCT05169840: Genetic Risk Stratification for Primary Prevention of CAD in Men and Pre & Post-menopausal Women |
|
|
| Recruiting | N/A | 2000 | US | Genetic Risk Score for Coronary Artery Disease, Conventional Risk Score for Coronary Artery Disease | St. Joseph's Hospital and Medical Center, Phoenix, Chandler Regional Medical Center, Mercy Gilbert Medical Center | Coronary Artery Disease, Genetic Predisposition to Disease | 06/24 | 06/24 | | |
| Eastman, Kate |
CHANGE AFIB, NCT05130268: Early Dronedarone Versus Usual Care to Improve Outcomes in Persons With Newly Diagnosed Atrial Fibrillation |
|
|
| Active, not recruiting | 4 | 3000 | US | Dronedarone, Multaq | American Heart Association, Duke Clinical Research Institute, Sanofi | Atrial Fibrillation | 06/24 | 12/24 | | |
